Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 ...

The phase 3 AQUILA study showed a 63.1% progression-free rate at 5 years with daratumumab versus 40.8% with active monitoring ...

Primary results from the phase 3 AQUILA study showed that subcutaneous daratumumab elicited a significant improvement in PFS ...

An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma ...

The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific ...

Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.

"This study provides strong evidence for the use of daratumumab as a treatment for high-risk smoldering multiple myeloma," says Dr. Rajkumar, the Edward W. and Betty Knight Scripps Professor of ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced data highlighting that DARZALEX® (daratumumab) subcutaneous (SC)-based regimens improve overall and sustained minimal residual ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition ...